ReviewWorld journal of gastrointestinal oncology2025
Artificial intelligence in the diagnosis and prognosis of intrahepatic cholangiocarcinoma: Applications and challenges.
Review in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a primary liver malignancy with increasing global incidence and mortality rates. The 5-year overall survival rate for patients with ICC is approximately 9%. Surgical resection currently represents the only curative treatment option. However, due to the high aggressiveness, insidious onset, and atypical clinical presentation of ICC, many patients either miss the optimal surgical window or experience early postoperative recurrence and metastasis. This poses significant challenges for hepatobiliary surgeons worldwide. Artificial intelligence (AI), as a prominent driver of technological advancement, offers promising new avenues for managing ICC. By leveraging powerful machine learning and deep learning algorithms, AI has demonstrated promising outcomes in ICC diagnosis, particularly in differentiating it from hepatocellular carcinoma, and in predicting critical prognostic factors such as early recurrence, lymph node metastasis, and microvascular invasion. These innovations can support clinical decision-making and ultimately improve patient outcomes. Future efforts should prioritize robust clinical studies evaluating the effectiveness of AI in ICC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.